DC Chemicals received good feedback from our customers.
MORE>>Featured Products
Cat. No. Product name CAS No.
DC60444 FX-909 Featured

FX-909(FX 909) is a first-in-class inverse agonist of the peroxisome proliferator-activated receptor gamma (PPARG) lineage transcription factor with EC50 of 1 nM and shows >2000-fold selectivity for PPARG over PPARA/PPARD - acting through a mechanism that promotes a repressive conformation of PPARG.

2924573-90-8
DC70648 NH-23-C2 Featured

NH-23-C2 (Caspase-2 inhibitor NH-23-C2) is a potent, selective and cell-permeable endogenous caspase-2 inhibitor, does not block caspase-3 or caspase-8.NH-23-C2 displays off-reactivity with cysteine and threonine proteases (cathepsins B, L, V, S).HCT116 cells were preincubated with NH-23-C2 inhibitor, MDM-2 cleavage was inhibited in a concentration-dependent manner (IC50 =3.11 μM).NH-23-C2 selectively block caspase-2 activity and caspase-2-mediated MDM-2 cleavage.

DC70620 MS934 Featured

MS934 (MS-934) is a VHL-recruiting MEK1/2 degrader (PROTAC) with HT29 DC50 of 18/9 nM for MEK1/2 degradation, respectively.MS934 is more potent at inhibiting the growth of HT-29, SK-MEL-28, H3122, and SUDHL1 cells. MS934 also displays good plasma exposure in mice.

2756323-15-4
DC70010 98N12-5 Featured

98N12-5 is an ionizable cationic lipid. It has been used in combination with other lipids in the generation of lipid nanoparticles (LNPs). LNPs containing 98N12-5 and encapsulating proprotein convertase subtilisin kexin type 9 (PCSK9) siRNA selectively accumulate in the liver and reduce total serum cholesterol levels in mice and rats and serum LDL levels in cynomolgus monkeys.

917572-74-8
DC59010 C14-4 (C14-494,Lipid B-4,Lipid B4) Featured

C14-4 (C14-494,Lipid B-4,Lipid B4) is a novel ionizable lipid with the highest T-cell transfection efficiency and low cytotoxicity.The C14-4 ionizable lipid has been explored for CAR-T therapy.To screen the excellent formulations for mRNA delivery, a lipid library of 24 ionizable lipids was constructed to make iLNPs, which were used to deliver luciferase mRNA into Jurkat cells.[115] The optimal iLNPs formulation was C14-4 iLNPs (C14-4 ionizable lipid, DOPE, chol, and PEG at a molar ratio of 35%, 16%, 46.5%, and 2.5%) (Figure 6c). The optimal dose of luciferase mRNA for C14-4 iLNPs was 30 ng. Compared with electroporated CAR T cells, the CAR T cells engineered via C14-4 iLNPs showed potent cancer-killing activity when they were cocultured with Nalm-6 acute lymphoblastic leukemia cells. To obtain a safer and more effective CAR mRNA delivery vehicle, the orthogonal design provided 256 potential formulations, and 16 representative iLNPs formulations were evaluated.Through evaluating the safety, delivery efficiency, and transfection efficiency of 16 iLNPs, the formulation B10 (C14-4 ionizable lipid, DOPE, chol, PEG at a molar ratio of 40%, 30%, 25%, and 2.5%) was screened out as the optimal performing formulation. The luciferase expression based on B10 formulation was increased threefold than the initial formulation. Reducing the accumulation and clearance of iLNPs in the liver can increase the expression of CAR mRNA in T cells, further improving the therapeutic effect of CAR-T. Studies have shown that cholesterol analogs can alter the mechanisms of intracellular circulation and enhance the delivery of mRNA, which may be related to the reduced recognition of iLNPs by the Niemann Pick C1 (NPC1) enzyme.The addition of a hydroxyl group to various locations in the cholesterol molecule can alter the binding kinetics between the modified cholesterol and NPC1, and reduced NPC1 recognition of cholesterol. The results showed that replacement of 25% and 50% 7 α-hydroxycholesterol for cholesterol in iLNPs improved mRNA delivery to primary human T cells in vitro by 1.8-fold and twofold, respectively.C14-4 is one of the ionizable lipids to efficiently deliver mRNA to Jurkat cells or primary human T cells. It will effectively promote the development of mRNA delivery by iLNPs for CAR-T therapy.

2639634-80-1
DC57046 ATX-100 Featured

ATX-100 is an ionizable cationic lipid (pKa = 6.38).1,2 It has been used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA. Intravenous administration of LNPs containing ATX-100 and encapsulating Factor VII siRNA decrease Factor VII blood levels in mice.2

2230647-37-5
DC53045 STM2457 Featured

STM2457 is in stock, and we can ship it immeidately. STM2457 is a potent inhibitor of METTL3/METTL14 catalytic activity with IC50 of 16.9 nM, Kd of 1.4 nM, respectively. STM2457 is highly specific for METTL3 and shows significant anti-leukaemic effect.

2499663-01-1
DC31024 Lipid 5 Featured

Lipid 5 is an amino lipid that affords efficient mRNA delivery in rodent and primate models. Lipid 5 shows optimal pharmacokinetics and non-toxic side effects.Replacement of the linoleic tail with a primary ester-containing lipid tail (Lipid 5) provids increased expression and optimal tissue clearance. The metabolite identification studies with Lipid 5 indicated that hydrolysis of the primary ester is the first step in the metabolism of the lipid[1].Clearance of Lipid 5 and MC3 from multiple mouse tissues is measured after dosing 0.05 mg/kg mRNA on days 1, 8, and 15 in CD-1 female mice. Liver and spleen have the highest levels of Lipid 5, however, significantly lower levels than MC3. Lipid 5 is detected in plasma, lung, and kidney, but not in heart[1].

2089251-33-0
DC31000 LP-01 Featured

LP-01 is a cationic lipids useful in the delivery of biologically active agents to cells and tissues.

1799316-64-5
DC10800 DLin-MC3-DMA Featured

D-Lin-MC3-DMA(MC3) is the most potent cationic lipid that has been synthesized for Lipid nanoparticles (LNPs) to deliver the siRNA.

1224606-06-7